Merck & Co. vs Boston Scientific
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma anchored by Keytruda ($25B cancer drug); $63.6B FY2024 revenue; Gardasil China collapse 2024 ($2B loss); Winrevair PAH approval 2024; Keytruda patent cliff 2028-2030 is defining challenge.
About
Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.
Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.
About
Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.